2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | ANNALS OF ONCOLOGY ANN ONCOL LetPub评分 9.7
51人评分
我要评分
声誉 10.0 影响力 9.5 速度 9.7 | |||||||||||||||||||||
| 期刊ISSN | 0923-7534 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1569-8041 | |||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 注册或登录后，查看影响因子和历年趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 1.40%注册或登录后，查看自引率趋势图 | |||||||||||||||||||||
| h-index | 210 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting. | |||||||||||||||||||||
| 期刊官方网站 | http://annonc.oxfordjournals.org/ | |||||||||||||||||||||
| 期刊投稿网址 | http://www.oxfordjournals.org/our_journals/annonc/for_authors/submission_online.html | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD, ENGLAND, OX2 6DP | |||||||||||||||||||||
| 出版商 | Oxford University Press | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 1990 | |||||||||||||||||||||
| 年文章数 | 125注册或登录后，查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 52.07% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 84.80% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 注册或登录后，查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0923-7534%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 很快,2-3周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较难 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 注册或登录后，查看自引率趋势图 |
| 注册或登录后，查看中科院SCI期刊分区趋势图 |
| 注册或登录后，查看年文章数趋势图 |
| 中国学者近期发表的论文 | |
| 1. | Biological background of the genomic variations of cf-DNA in healthy individuals. Author: Liu J1,2, Chen X3, Wang J4,5, Zhou S1, Wang CL1, Ye MZ6, Wang XY1, Song Y1, Wang YQ1, Zhang LT1, Wu RH1, Yang HM4,5, Zhu SD4, Zhou MZ6, Zhang XC7, Zhu HM3, Qian ZY3. Journal: Ann Oncol. 2019 Mar 1;30(3):464-470. doi: 10.1093/annonc/mdy513. PubMed DOI |
| 2. | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Author: Muro K1, Van Cutsem E2, Narita Y1, Pentheroudakis G3, Baba E4, Li J5, Ryu MH6, Zamaniah WIW7, Yong WP8, Yeh KH9,10, Kato K11, Lu Z12, Cho BC13, Nor IM14, Ng M15, Chen LT16, Nakajima TE17, Shitara K18, Kawakami H19, Tsushima T20, Yoshino T18, Lordick F21,22, Martinelli E23, Smyth EC24, Arnold D25, Minami H26, Tabernero J27, Douillard JY28. Journal: Ann Oncol. 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502. PubMed DOI |
| 3. | Virtual microdissection in the molecular subtyping of head and neck squamous carcinoma-a 'Virtual Reality' of the tumor microenvironment? Author: Ma BBY1. Journal: Ann Oncol. 2019 Jan 1;30(1):8-10. doi: 10.1093/annonc/mdy516. PubMed DOI |
| 4. | Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Author: Wu YL1, Planchard D2, Lu S3, Sun H4, Yamamoto N5, Kim DW6, Tan DSW7, Yang JC8, Azrif M9, Mitsudomi T10, Park K11, Soo RA12, Chang JWC13, Alip A14, Peters S15, Douillard JY16. Journal: Ann Oncol. 2019 Feb 1;30(2):171-210. doi: 10.1093/annonc/mdy554. PubMed DOI |
| 5. | HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Author: Wang Y1, Jiang T1, Qin Z2, Jiang J3, Wang Q3, Yang S1, Rivard C4, Gao G1, Ng TL4, Tu MM5,6, Yu H4, Ji H1,2, Zhou C1, Ren S1,4, Zhang J7, Bunn P4, Doebele RC4, Camidge DR4, Hirsch FR4. Journal: Ann Oncol. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542. PubMed DOI |
| 6. | Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Author: Dong D1,2,3, Tang L2, Li ZY4, Fang MJ1,3, Gao JB5, Shan XH6, Ying XJ4, Sun YS2, Fu J2, Wang XX6, Li LM5, Li ZH7, Zhang DF7, Zhang Y4, Li ZM4, Shan F4, Bu ZD4, Tian J1,3,8, Ji JF4. Journal: Ann Oncol. 2019 Mar 1;30(3):431-438. doi: 10.1093/annonc/mdz001. PubMed DOI |
| 7. | OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Author: Robson ME1, Tung N2, Conte P3, Im SA4, Senkus E5, Xu B6, Masuda N7, Delaloge S8, Li W9, Armstrong A10, Wu W11, Goessl C11, Runswick S12, Domchek SM13. Journal: Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012. PubMed DOI |
| 8. | Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. Author: Zhao C1,2, Miao J2, Shen G3,4, Li J5, Shi M6, Zhang N7, Hu G8, Chen X9, Hu X7, Wu S10, Chen J11, Shao X3, Wang L2, Han F12, Mai H2, Chua MLK13,14, Xie C1. Journal: Ann Oncol. 2019 Apr 1;30(4):637-643. doi: 10.1093/annonc/mdz020. PubMed DOI |
| 9. | Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3). Author: Zuo H1, Ueland PM2,3, Midttun Ø4, Tell GS1, Fanidi A5,6, Zheng W7, Shu X7, Xiang Y8, Wu J7, Prentice R9, Pettinger M9, Thomson CA10, Giles GG11,12, Hodge A11,12, Cai Q7, Blot WJ7, Johansson M13, Hultdin J14, Grankvist K14, Stevens VL15, McCullough ML15, Weinstein SJ16, Albanes D16, Ziegler RG16, Freedman ND16, Caporaso NE16, Langhammer A17, Hveem K17, Næss M17, Buring JE18,19, Lee I18,19, Gaziano JM20,21, Severi G22,23, Zhang X24, Stampfer MJ24,19,25, Han J26, Zeleniuch-Jacquotte A27, Marchand LL28, Yuan J29,30, Wang R29, Koh W31, Gao Y32, Ericson U33, Visvanathan K34, Jones MR34, Relton C35,36, Brennan P5, Johansson M5, Ulvik A4. Journal: Ann Oncol. 2019 Mar 1;30(3):478-485. doi: 10.1093/annonc/mdz002. PubMed DOI |
| 10. | 31PComprehensive genomic profiling of Chinese esophageal squamous cell carcinoma patients. Author: Ji Y1, Wu Y2, Fu W3, Liu L4, Tian Z5, Wen S5, Zhang K6, Yao M7, Liu A7, Zhou Y7. Journal: Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz026.002. doi: 10.1093/annonc/mdz026.002. PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共4条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
